Abstract
Chemotherapy and irradiation of organs adjacent to the target volumes are associated with significant acute gastrointestinal and genito-urinary toxicity and a high rate of post-operative complications and late toxicities. Assessing radiochemotherapy-related side-effects is hard because inter-study comparisons may be hampered by use of different toxicity scales, cohort sizes, study time-points, and study focus which may analyse, for example, only single side effects and their grades or all side-effects according to grade. Moreover, some side effects were under-analysed and under-reported. Finally, while increased early toxicity has been recognized in all trials, data are less clear about late toxicity. With the aim of improving the rectal cancer patient’s relationship with the radiation oncologist in the pre-treatment consultation this chapter answers the most common questions asked by a candidate for neo-adjuvant radio-chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933
Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625
Bosset JF, Collette L, Calais G et al (2006) EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123
Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72(1):15–24
Roh MS, Colangelo LH, O’Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27(31):5124–5130
Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in unresectable rectal cancer. J Clin Oncol 26(22):3687–3694
Sainato A, Cernusco LNV, Valentini V et al (2014) No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113(2):223–229
Appelt AL, Bentzen SM, Jakobsen A et al (2015) Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta Oncol 54(2):179–186
Wolff HA, Conradi LC, Schirmer M et al (2011) Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist 16(5):621–631
Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588
Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 30(31):3827–3833
François E, Azria D, Gourgou-Bourgade S et al (2014) Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol 110(1):144–149
Martel G, Al-Suhaibani Y, Moloo H et al (2008) Neoadjuvant therapy and anastomotic leak after tumor-specific mesorectal excision for rectal cancer. Dis Colon Rectum 51(8):1195–1201
Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20):2773–2780
An X, Lin X, Wang F-H et al (2013) Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer 49(4):843–851
Valentini V, De Paoli A, Barba M.C. et al (2014) Capecitabine based preoperative chemo-RT in rectal cancer intensified by RT dose or oxaliplatin: the INTERACT trial. OC 0494, p 204, ESTRO 33, Vienna, 4–8 Apr 2014
Brændengen M, Tveit KM, Bruheim K et al (2011) Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys 81(4):1017–1024
Coco C, Valentini V, Manno A et al (2007) Functional results after radiochemotherapy and total mesorectal excision for rectal cancer. Int J Color Dis 22(8):903–910
Parekh A, Truong MT, Pashtan I et al (2013) Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res 6(5–6):137–143
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Aristei, C., Lancellotta, V., Lupattelli, M. (2018). Which Side Effects Should Be Described to Patients Before Neoadjuvant Radio-Chemotherapy Treatment?. In: Valentini, V., Schmoll, HJ., van de Velde, C. (eds) Multidisciplinary Management of Rectal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-43217-5_32
Download citation
DOI: https://doi.org/10.1007/978-3-319-43217-5_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43215-1
Online ISBN: 978-3-319-43217-5
eBook Packages: MedicineMedicine (R0)